🇺🇸 FDA
Pipeline program

CISPLATIN, INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., GEMCITABINE, MYCOPHENOLATE MOFETIL

D933AC00001

Phase 3 small_molecule active

Quick answer

CISPLATIN, INFLIXIMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., GEMCITABINE, MYCOPHENOLATE MOFETIL for First-line patients with advanced biliary tract cancers (BTC) is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
First-line patients with advanced biliary tract cancers (BTC)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials